Liposomal Amphotericin B (AmBisome) in the Treatment of Neonatal Candidiasis in Very Low Birth Weight Infants

Juster-Reicher, Ada; Leibovitz, Eugene; Linder, Nehama; Amitay, Moshe; Flidel-Rimon, Orna; Even-Tov, Smadar; Mogilner, B.M.; Barzilai, Aviv

doi:10.1007/s150100070040

Cited by 83 publications

(39 citation statements)

References 24 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, there is notably less reported renal and liver toxicity with LAMB (Table 3, Supplementary Table 2, http://links.lww.com/COID/A1). Several authors reported that patients tolerated LAMB better after being switched from DAMB [21,46,47].…”

Section: Amphotericin B Lipid Formulationsmentioning

confidence: 99%

Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy – is there a ‘right’ choice?

Turkova

Roilides

2011

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

show abstract

Section: Amphotericin B Lipid Formulationsmentioning

confidence: 99%

Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy – is there a ‘right’ choice?

Turkova

Roilides

2011

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…The age of onset of disseminated fungal infection among NICU patients has a wide range, with some cases occurring in the first week of life and others occurring later than 6 months of age. Among VLBW infants, the mean onset of infection ranges from 15 to 33 days of age (31,234,366,402). Fungal sepsis may occur earlier in infants with lower gestational age and birth weight.…”

Section: Vol 17 2004 Infections In Very-low-birth-weight Infants 661mentioning

confidence: 99%

Clinical Microbiology of Bacterial and Fungal Sepsis in Very-Low-Birth-Weight Infants

2004

View full text Add to dashboard Cite

Twenty percent of very-low-birth-weight (<1500 g) preterm infants experience a serious systemic infection, and despite advances in neonatal intensive care and antimicrobials, mortality is as much as threefold higher for these infants who develop sepsis than their counterparts without sepsis during their hospitalization. Outcomes may be improved by preventative strategies, earlier and accurate diagnosis, and adjunct therapies to combat infection and protect the vulnerable preterm infant during an infection. Earlier diagnosis on the basis of factors such as abnormal heart rate characteristics may offer the ability to initiate treatment prior to the onset of clinical symptoms. Molecular and adjunctive diagnostics may also aid in diagnosing invasive infection when clinical symptoms indicate infection but no organisms are isolated in culture. Due to the high morbidity and mortality, preventative and adjunctive therapies are needed. Prophylaxis has been effective in preventing early-onset group B streptococcal sepsis and late-onset Candida sepsis. Future research in prophylaxis using active and passive immunization strategies offers prevention without the risk of resistance to antimicrobials. Identification of the differences in neonatal intensive care units with low and high infection rates and implementation of infection control measures remain paramount in each neonatal intensive care unit caring for preterm infants

show abstract

“…JusterReicher el al. [13] also found no major adverse effects in 24 VLBW infants treated with AmBisome (mean GA of 26 weeks), and Weitkamp et al [14] reported the absence of nephrotoxicity related to AmBisome therapy in 21 VLBW infants (GA age 23-31 weeks). In another study of 52 preterm infants, Linder et al showed an improvement in renal function during treatment with three amphotericin B preparations.…”

Section: Discussionmentioning

confidence: 99%

“…However, ABLC may also induce azotemia, a decreased glomerular filtration rate, and severe hypokalemia [8,9]. The ABLC and other lipid formulations of amphotericin B, such liposomal amphotericin B, have been used in preterm infants, term infants, children, and adults [7,8,[10][11][12][13][14][15][16][17]. Although a number of studies have compared the different types of lipid formulations of amphotericin B or compared a lipid formulation and regular amphotericin B in infants and adults [7,9], the effect of ABLC (Abelcet) on renal function and serum electrolytes in VLBW infants has not been fully investigated.…”

Section: Introductionmentioning

confidence: 99%

Effect of amphotericin B lipid complex (ABLC) in very low birth weight infants

et al. 2009

View full text Add to dashboard Cite

The aim of this retrospective, case-control study was to determine the effect of the amphotericin B lipid complex (ABLC) on serum creatinine (SCr), blood urea nitrogen (BUN), sodium (Na), and potassium (K) in very low birth weight (VLBW) infants. Medical records of all VLBW infants who were admitted to our Neonatal Intensive Care Unit between May 1998 and May 2006 and had received ABLC for at least 2 weeks were reviewed for patient demographics, use of medications (ABLC, diuretics, xanthines, indomethacin, vancomycin, gentamicin, pressors, and inotropes), fluid intake, urinary output, and serum electrolytes. Thirty-five patients who received ABLC were identified and matched by gestational age (GA) to 35 patients who served as controls. Infants who received ABLC had an average GA of 25.7 +/- 2.1 weeks and a birth weight of 764 +/- 196 g. Between day 1 and 14 of ABLC treatment, the BUN decreased from 17.5 +/- 11.5 to 10.5 +/- 6.8 mg/dl (p = 0.01), the SCr varied between 0.78 +/- 0.32 and 0.69 +/- 0.32 mg/dl, Na varied between 136.6 +/- 5.8 and 137.8 +/- 3.6 mEq/l, and K varied between 4.8 +/- 0.9 and 4.9 +/- 0.6 mEq/l, respectively. Based on these results, we conclude that treatment with ABLC for 2 weeks did not increase BUN or SCr, nor decrease Na or K in VLBW infants.

show abstract

Liposomal Amphotericin B (AmBisome) in the Treatment of Neonatal Candidiasis in Very Low Birth Weight Infants

Abstract: AmBisome represents an effective, safe and convenient antifungal agent in the therapy of systemic fungal infections in very low birth weight infants.

Cited by 83 publications

References 24 publications

Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy – is there a ‘right’ choice?

Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy – is there a ‘right’ choice?

Clinical Microbiology of Bacterial and Fungal Sepsis in Very-Low-Birth-Weight Infants

Effect of amphotericin B lipid complex (ABLC) in very low birth weight infants

Contact Info

Product

Resources

About